Monahan Joseph

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
12
Insider Sells Sum
$2.61M

Insider Activity of Monahan Joseph

According to the SEC Form 4 filings, Monahan Joseph, being in a position of

  1. Chief Scientific Officer at Aclaris Therapeutics, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 6000 shares for $30,460,
    over all time since 2021-06-02, has bought 0 shares, and sold 164965 shares for $2.61M.

The largest sale of all time was on 2021-06-02 and amounted to 43580 shares of Aclaris Therapeutics, Inc. for $942,873.

Biography of Monahan Joseph

No biography is available at this moment.

2023-10-23SaleAclaris Therapeutics, Inc.
ACRS
Chief Scientific Officer
6,000
0.0086%
$5.08$30,460-76.1%
2023-08-21SaleAclaris Therapeutics, Inc.
ACRS
Chief Scientific Officer
6,000
0.0084%
$7.32$43,895-83.45%
2023-06-20SaleAclaris Therapeutics, Inc.
ACRS
Chief Scientific Officer
6,000
0.0087%
$10.28$61,663-88.42%
2023-03-03SaleAclaris Therapeutics, Inc.
ACRS
Chief Scientific Officer
16,037
0.0237%
$12.63$202,615-41.47%
2023-03-02SaleAclaris Therapeutics, Inc.
ACRS
Chief Scientific Officer
14,800
0.0217%
$12.37$183,024-40.65%
2023-02-15SaleAclaris Therapeutics, Inc.
ACRS
Chief Scientific Officer
5,000
0.0075%
$13.06$65,311-40.83%
2022-12-15SaleAclaris Therapeutics, Inc.
ACRS
Chief Scientific Officer
5,000
0.0076%
$15.88$79,412-46.17%
2022-10-17SaleAclaris Therapeutics, Inc.
ACRS
Chief Scientific Officer
5,000
0.0074%
$15.98$79,908-39.07%
2022-04-18SaleAclaris Therapeutics, Inc.
ACRS
Chief Scientific Officer
30,000
0.046%
$16.28$488,298-5.71%
2022-03-10SaleAclaris Therapeutics, Inc.
ACRS
Chief Scientific Officer
27,165
0.0434%
$15.71$426,803-2.88%
2022-02-09SaleAclaris Therapeutics, Inc.
ACRS
Chief Scientific Officer
383
0.0006%
$12.68$4,857+22.76%
2021-06-02SaleAclaris Therapeutics, Inc.
ACRS
Chief Scientific Officer
43,580
0.0804%
$21.64$942,873-30.08%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.